Episode Details
Back to Episodes
COVID-19 Update: Independent Conference Coverage of ECCMID 2023
Episode 279
Published 2 years, 10 months ago
Description
In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:
- Treatment in special populations
- REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
- Remdesivir and readmission for COVID-19 in immunocompromised patients
- Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
- Management of patients with severe disease
- RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
- Real-world study of tocilizumab vs baricitinib for severe COVID-19
- Novel antivirals
- Ensitrelvir
- Bemnifosbuvir
- Novel vaccines
- NB2155
- AZD2816/AZD1222
- qNIV/CoV2373
- GRT-R910
- NVX-CoV2373 in people with HIV
Faculty:
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Professor of Microbial Diseases
Centre for Experimental Pathogen Host Research
University College Dublin
Dublin, Ireland
Content based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.
Link to full program:
bit.ly/3niXGJ6
Link to downloadable slides:
bit.ly/3LUFejG
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.